Teva Retains Top Slot In Generics/Biosimilar Rankings As Industry Faces US Pushback
With Mylan snapping at its heels, Israel’s Teva managed to retain top slot in the latest Generics Bulletin rankings. Severe pricing and margin pressures in the US market made like difficult for generics companies in 2017, with eight of the top 20 firms reporting year on year sales declines.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.